Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?

3 weeks ago 31

Soumya Eswaran

Tue, August 4, 2026 astatine 10:15 AM CDT 3 min read

Baron Capital, an concern absorption company, released its Q2 2026 capitalist missive for the "Baron Health Care Fund". A transcript of the missive is disposable to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% summation for the Russell 3000 Health Care Index and the 15.44% summation for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% connected an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong banal enactment successful pharmaceuticals, biotechnology, wellness attraction equipment, and beingness sciences tools and services supported the Fund's outperformance, though constricted vulnerability to managed attraction stocks reduced comparative returns. The Fund remains affirmative connected wellness attraction owed to improving biotechnology funding, beardown acquisition activity, recovering managed attraction margins, and maturation from an aging population, chronic disease, aesculapian innovation, and higher wellness attraction spending. In addition, delight cheque the Fund's apical 5 holdings to cognize the champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Eli Lilly and Company (NYSE:LLY) arsenic a notable show contributor. Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets quality pharmaceutical products successful the United States and internationally. On August 03, 2026, Eli Lilly and Company (NYSE:LLY) closed astatine $1,121.36 per share. The one-month instrumentality of Eli Lilly and Company (NYSE:LLY) was -9.24%, and its shares gained 46.40% implicit the past 52 weeks. Eli Lilly and Company (NYSE:LLY) has a marketplace capitalization of $1.06 trillion.

Baron Health Care Fund stated the pursuing regarding Eli Lilly and Company (NYSE:LLY) in its Q2 2026 capitalist letter:

"Pharmaceutical institution Eli Lilly and Company (NYSE:LLY), presently champion known for its diabetes and obesity GLP-1 therapies, contributed to show arsenic commercialized execution and pipeline information reinforced capitalist assurance successful the company's semipermanent leadership. All 3 large pharmacy payment managers present screen Lilly's obesity portfolio, including its caller regular oral GLP-1, Foundayo. This marks a reversal from past summer, erstwhile CVS Caremark provided preferred sum for Novo Nordisk's Wegovy and raised concerns astir a imaginable terms war. The displacement suggests that patients and physicians similar Zepbound and are driving demand. Clinical proceedings information further reinforces our presumption that Lilly has 1 of the strongest next-generation metabolic pipelines successful the industry. Phase 3 information showed retatrutide delivered value nonaccomplishment successful the high-20% scope astatine higher doses and astir 20% astatine little doses, portion maintaining fantabulous tolerability. We are besides excited about eloralintide, wherever Phase 2 information showed Zepbound-like efficacy and tolerability, with operation information expected soon. Long term, we proceed to presumption Lilly's portfolio arsenic the golden modular successful a class that we judge tin transcend $150 billion."

Read Entire Article